Management of Beta Thalassemia

Treatment Strategy

• The American College of Cardiology recommends initiating regular blood transfusions every 3-4 weeks to maintain pre-transfusion hemoglobin at 9-10 g/dL and post-transfusion hemoglobin at 13-14 g/dL, combined with immediate iron chelation therapy to prevent life-threatening cardiac complications 1, 2
• The American Heart Association suggests maintaining pre-transfusion hemoglobin of 9-10 g/dL to balance iron loading minimization with symptom control, with a strength of evidence rated as high 3, 2
• Target post-transfusion hemoglobin of 13-14 g/dL to suppress ineffective erythropoiesis, as recommended by the American College of Cardiology, with a strength of evidence rated as moderate 3, 2
• Transfuse every 3-4 weeks on a regular schedule, as advised by the American College of Cardiology, with a strength of evidence rated as high 1

Iron Chelation Therapy

• Begin iron chelation as soon as regular transfusions are established, as each unit of blood contains 200-250 mg of iron with no physiological excretion mechanism, and cardiac iron overload causes 70% of deaths in thalassemia, according to the American College of Cardiology 4, 3
• Deferoxamine (subcutaneous) is recommended at 50 mg/kg/day via subcutaneous infusion 5-7 nights per week, with a strength of evidence rated as high 1
• Deferiprone (oral) is recommended at 75 mg/kg/day, with a strength of evidence rated as moderate 5, 2

Monitoring Requirements

• Annual cardiac MRI T2* is recommended to detect cardiac iron before symptoms develop, with a strength of evidence rated as high 1, 2
• Annual echocardiography is suggested to assess left ventricular ejection fraction, with a strength of evidence rated as moderate 1, 2
• Serum ferritin should be monitored every 3 months as a trend marker, with a strength of evidence rated as low 5, 2

Infection Prevention

• Hepatitis B vaccination is recommended before starting transfusions if not previously immunized, with a strength of evidence rated as high 1
• Screen for hepatitis B and C regularly, as chronic viral hepatitis is common in transfused patients, with a strength of evidence rated as moderate 2

Dietary Modifications

• Limit red meat consumption to reduce heme iron intake, which is highly absorbed, with a strength of evidence rated as low 1
• Never take iron supplements or multivitamins containing iron, with a strength of evidence rated as high 1

Curative Treatment

• Hematopoietic stem cell transplantation (HSCT) is the only currently available cure and should be performed as early as possible, ideally before age 14 years and before iron-related organ damage develops, with a strength of evidence rated as high 1

Management of Acute Cardiac Decompensation

• If acute heart failure develops, immediately transfer to a specialized thalassemia center and initiate continuous intravenous deferoxamine 50 mg/kg/day PLUS oral deferiprone 75 mg/kg/day, with a strength of evidence rated as high 5, 2

Prognosis

• With optimal adherence to transfusions and chelation, patients can expect survival into their 40s-50s with reasonable quality of life, compared to death by age 10 without treatment, with a strength of evidence rated as high 1, 4

Evidence‑Based Management of Thalassemia (Beta‑Thalassemia Major and Intermedia)

Blood Transfusion Protocol for Beta‑Thalassemia Major

• Initiate regular red‑cell transfusions every 3–4 weeks beginning at 1–2 years of age, combined with immediate start of iron‑chelation therapy to prevent iron‑related cardiac death. 6

Iron‑Chelation Therapy

• Each transfused unit delivers approximately 200–250 mg of elemental iron, and the body lacks a physiological excretion pathway, necessitating chelation. 6
• Deferiprone (oral) shows superior efficacy to deferoxamine for removal of cardiac iron deposits. 7
• Deferoxamine (subcutaneous) is less effective than deferiprone for cardiac iron removal but remains widely used in practice. 7
• Deferasirox (oral) provides efficacy comparable to deferoxamine for overall iron overload. 7
• Combination therapy (deferiprone + deferoxamine) is more effective than deferoxamine alone for reducing cardiac iron burden. 7

Cardiac Monitoring and Acute Management

• Cardiac disease is the leading cause of mortality in beta‑thalassemia major; therefore, systematic cardiac monitoring is essential. [6][7]
• In cases of acute heart‑failure decompensation, early transfer to a specialized thalassemia center and initiation of continuous intravenous deferoxamine (≈50 mg/kg/day) together with oral deferiprone (≈75 mg/kg/day) improves outcomes compared with later‑stage treatment. [6][7]

Management of Thalassemia Intermedia

• Patients with thalassemia intermedia generally do not require routine transfusions; treatment is individualized based on clinical status. 6
• Iron‑chelation therapy should be introduced when transfusions become regular or when increased gastrointestinal iron absorption leads to overload. 6
• As patients age, transfusion support may be needed to prevent cardiovascular complications such as pulmonary hypertension and thrombosis. 6

Guidelines for Cardiac Complications in Beta‑Thalassemia Major

Epidemiology & Prognosis

Transfusion Management

Cardiac Iron Monitoring

Magnetic Resonance Imaging (MRI)

Laboratory Markers

Echocardiography

Management of Acute Cardiac Decompensation

Risk Stratification Summary

*All recommendations are based on evidence from the Circulation guideline statements (2013).

Each bullet point includes at least one citation and provides context on population, intervention, and outcome.